Skip to main content

Advertisement

Table 4 Distribution of 65 Zn 7 days after gavage administration of 65 ZnO or SiO 2 -coated 65 ZnO NPs in rats

From: Bioavailability, distribution and clearance of tracheally-instilled and gavaged uncoated or silica-coated zinc oxide nanoparticles

  65ZnO SiO2-coated65ZnO
  Mean ± SE Mean ± SE
Lungs 0.04 ± 0.01 0.06 ± 0.01
Blood 0.23 ± 0.03 0.22 ± 0.04
Lymph nodes 0.02 ± 0.003 0.06 ± 0.01 #
Bone marrow 0.49 ± 0.06 0.47 ± 0.09
Bone 1.62 ± 0.26 2.20 ± 0.45
Skin 1.13 ± 0.14 1.77 ± 0.29
Brain 0.03 ± 0.002 0.04 ± 0.005
Skeletal muscle 2.45 ± 0.36* 0.20 ± 0.03
Testes 0.14 ± 0.01 0.19 ± 0.03
Kidneys 0.08 ± 0.01 0.09 ± 0.01
Spleen 0.02 ± 0.004 0.02 ± 0.004
Heart 0.03 ± 0.003 0.02 ± 0.004
Liver 0.58 ± 0.07 0.71 ± 0.09
Stomach 0.07 ± 0.01 0.09 ± 0.01
Small intestine 0.25 ± 0.03 0.36 ± 0.05
Large intestine 0.09 ± 0.02 0.11 ± 0.01
Cecum 0.13 ± 0.02 0.12 ± 0.02
Total recovered 100.59 ± 2.56* 83.40 ± 2.42
  1. Data are mean ± SE% gavaged dose, n = 5/group.
  2. Total recovered = sum of 65Zn in analyzed organs, feces and urine.
  3. *P < 0.05, ZnO > SiO2-coated ZnO.
  4. # P <0.05, SiO2-coated ZnO > ZnO.